12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Evolocumab: Phase III data

Top-line data from the double-blind, 6-arm, international Phase III MENDEL-2 trial in 614 patients with high cholesterol (LDL-C levels of >=100 mg/dL and <190 mg/dL) who were not receiving lipid-lowering therapy showed that subcutaneous evolocumab given monthly at 420 mg and every 2 weeks at 140 mg each met the co-primary endpoints of a greater percent reduction in LDL-C from baseline to week 12 and a greater mean percent reduction in LDL-C from baseline to weeks 10 and 12 compared to both placebo and once-daily oral ezetimibe. To achieve statistical significance on each endpoint, Amgen said each evolocumab regimen had to achieve a p-value of...

Read the full 503 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >